UBS raised the firm’s price target on Eli Lilly (LLY) to $1,080 from $895 and keeps a Buy rating on the shares. The firm updated its model following the Q3 earnings report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Denali says chief medical officer Carole Ho to depart to join Eli Lilly
- Eli Lilly GLP-1 pricing deal ‘probably a good tradeoff,’ says BofA
- GLP-1 price cuts limit Hims advantage, says Needham
- Eli Lilly confirms weight loss drug agreement with U.S. government
- FDA awards second batch of National Priority Vouchers